Celularity appoints veteran pharmaceutical executive as chief medical officer

Kilcoyne brings more than 15 years of  experience to clinical-stage biotechnology company

Florham Park-based Celularity on Monday announced that Dr. Adrian Kilcoyne has been appointed executive vice president, chief medical officer and head of global medical affairs, patient safety and patient affairs, effective immediately.

Kilcoyne brings over 15 years of clinical experience to the clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, having previously served in research & development, medical affairs and commercialization roles, primarily focused on oncology. He has a track record of advancing early-stage clinical programs through commercialization and will provide senior leadership to advance Celularity’s clinical pipeline toward U.S. Food and Drug Administration approval.

“It is with great pleasure that we welcome Dr. Kilcoyne to Celularity’s leadership team during this critical stage of our growth trajectory,” Dr. Robert Hariri, founder, chairman and CEO of Celularity, stated. “Dr. Kilcoyne will play a fundamental role in advancing our clinical pipeline, including our three Phase 1 studies in acute myeloid leukemia, glioblastoma multiforme and gastric cancer, and one IND-pending program in B-cell malignancies, all of which utilize our next-generation placental-derived cellular therapeutic candidates. I am confident Dr. Kilcoyne’s expertise and deep industry knowledge will help to accelerate Celularity’s achievement of key clinical development milestones and to establish Celularity as a leader in cellular immunotherapies.”

“I am excited to be joining such a talented and experienced group of professionals, and look forward to working as part of the leadership team to support and execute on Celularity’s vision,” Kilcoyne said. “Natural killer cells, especially those derived from placental cells, are scalable and have potential to confer greater safety and efficacy, the latter due to their inherent stemness. I am optimistic that, by leveraging this unique class of cells, Celularity will be successful in advancing therapies for the unmet clinical need in cancer, infectious and degenerative diseases.”

Most recently, Kilcoyne served as the chief medical officer of Humanigen, where he was responsible for building its oncology and immunology portfolio focused on the cytokine pathway, CAR-T therapy related toxicity and antibody drug conjugates in solid tumors. Before that, he served as an integral member of the executive team at AstraZeneca as the vice president of global oncology evidence generation and external alliances. During his time at AstraZeneca, he was responsible for the creation, development and delivery of the fully integrated global evidence strategy.